An Ovarian Cancer Expert Looks Back to Residency

Robert L. Coleman, MD


May 13, 2021

Dr Robert Coleman, chief scientific officer for the US Oncology Network, reflects on his first experiences with ovarian cancer patients in residency. Coleman remembers clearly how difficult it was to help ovarian cancer patients get through the night with their chemotherapy, and how the development of the 5-HT3 receptor blockers for highly emetogenic chemotherapy was a game-changing moment in supportive care.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.